

BPC-157 + TB-500 Blend + GHK-Cu Set
BPC-157 + TB-500 Blend 10mg + GHK-Cu 50mg. A combined repair and dermal-matrix research set.


Bundle
CJC-1295 + Ipamorelin Blend 10mg + Tesamorelin 5mg. A GHRH analog / ghrelin-receptor agonist blend paired with a growth-hormone-releasing factor analog.
Select size
Quantity
Total
$131.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
COA pending. The certificate for this lot will be uploaded to our COA library as soon as we have it.
Have a question?
For research use only. Not for human consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
Every vial carries its own batch number, exactly as it would if bought separately. Every certificate is published and available for review. No published literature characterises this combination as a single entity.
A combined GHRH analog and ghrelin-receptor agonist preparation used in secretagogue research.
COA pending. The certificate for this lot will be uploaded to our COA library as soon as we have it.
Full research notes and sources for CJC-1295 + Ipamorelin Blend →A growth-hormone-releasing factor analog examined in endocrine-pathway research models.
Certificate of Analysis: J_0726-01-TES10
Full research notes and sources for Tesamorelin →A co-formulation of two compounds that act on different receptors: CJC-1295, a GHRH-receptor analog developed by ConjuChem, and ipamorelin, a selective growth-hormone secretagogue described by Novo Nordisk researchers in 1998. The pairing is a supplier formulation; the combination itself has no independent discovery history or characterisation.
The interest in pairing these two is mechanistic rather than empirical: they engage two separate receptor systems on the somatotroph — the GHRH receptor and the ghrelin/growth-hormone-secretagogue receptor (GHS-R1a). Each is characterised independently in the literature cited under its own entry. No peer-reviewed work characterises this specific blend as a single entity. Neither constituent is FDA-approved for human use, and both classes appear on the WADA Prohibited List.
Tesamorelin is a synthetic analog of growth-hormone-releasing factor, structurally GHRH(1–44) with a trans-3-hexenoyl group attached at the N-terminus. That modification protects the peptide from dipeptidyl peptidase-4 cleavage, the enzymatic step that limits native GHRH. It was developed by Theratechnologies, reviewed as an investigational drug in 2009, and is one of very few compounds in this catalog with an approved human indication — it was reviewed by the FDA and authorised in 2010 for a narrow, specific use. The material supplied here is a research chemical, not that approved product.
Characterised as a GHRH-receptor agonist at the anterior pituitary. Its distinguishing structural feature is N-terminal modification conferring resistance to DPP-4 degradation, which is what separates it pharmacologically from unmodified GHRH(1–44). The material supplied here is a research chemical and is not the approved pharmaceutical product, is not prescribed, and carries no approved indication in this form. GHRH analogs appear on the WADA Prohibited List.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Summaries of published literature for research reference only. Not a claim about any product’s effect.
Batch releases & restocks
Every certificate is published and available for review. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.


BPC-157 + TB-500 Blend 10mg + GHK-Cu 50mg. A combined repair and dermal-matrix research set.


GLOW Blend 70mg + GHK-Cu 50mg. Copper-peptide focused preparation set for dermal research models.


KLOW Blend 80mg + KPV 10mg. A four-compound blend paired with an alpha-MSH fragment for multi-pathway research.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.